Xiao Fang Pharma 小方制药
28 significant filings since 29 May 2026: 3 on regulatory inquiry, 14 on equity incentive and 6 on share issue, and 3 other kinds. The latest, on 27 Aug 2026: 关于2026年中期利润分配方案的公告. 1 unverified report logged, the latest on 3 Sep 2026.
自 29 May 2026 起有 28 份重大公告：regulatory inquiry 3 份、equity incentive 14 份、share issue 6 份，另有 3 类。最新一份（27 Aug 2026）：关于2026年中期利润分配方案的公告。记录了 1 条未经核实的报道，最新一条见于 3 Sep 2026。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 0 brokers | 0 brokers |
| 7 days ago | 0 brokers | 0 brokers |
| 30 days ago | 0 brokers | 0 brokers |
| 60 days ago | 0 brokers | 0 brokers |
| 90 days ago | 0 brokers | 0 brokers |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 1.